Your browser doesn't support javascript.
loading
Minimum important difference of the EQ-5D-5L and EQ-VAS in fibrotic interstitial lung disease.
Tsai, Amy Po Yu; Hur, Seo Am; Wong, Alyson; Safavi, Mohsen; Assayag, Deborah; Johannson, Kerri A; Morisset, Julie; Fell, Charlene; Fisher, Jolene H; Manganas, Hélène; Shapera, Shane; Cox, Gerard; Gershon, Andrea S; Hambly, Nathan; Khalil, Nasreen; To, Teresa; Wilcox, Pearce George; Halayko, Andrew; Kolb, Martin Rj; Ryerson, Christopher J.
Afiliação
  • Tsai APY; The University of British Columbia Department of Medicine, Vancouver, British Columbia, Canada.
  • Hur SA; The University of British Columbia Department of Medicine, Vancouver, British Columbia, Canada.
  • Wong A; The University of British Columbia Department of Medicine, Vancouver, British Columbia, Canada.
  • Safavi M; Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, British Columbia, Canada.
  • Assayag D; Respiratory Evaluation Sciences Program, Collaboration for Outcomes Research and Evaluation, Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, British Columbia, Canada.
  • Johannson KA; McGill University Department of Medicine, Montreal, Quebec, Canada.
  • Morisset J; Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Fell C; Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
  • Fisher JH; Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
  • Manganas H; University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
  • Shapera S; Département de Médecine, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.
  • Cox G; University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
  • Gershon AS; Firestone Institute for Respiratory Health, McMaster University Department of Medicine, Hamilton, Ontario, Canada.
  • Hambly N; University of Toronto Faculty of Medicine, Toronto, Ontario, Canada.
  • Khalil N; Medicine, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
  • To T; Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Wilcox PG; Firestone Institute for Respiratory Health, McMaster University Department of Medicine, Hamilton, Ontario, Canada.
  • Halayko A; The University of British Columbia Department of Medicine, Vancouver, British Columbia, Canada.
  • Kolb MR; Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Ryerson CJ; University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada.
Thorax ; 76(1): 37-43, 2021 01.
Article em En | MEDLINE | ID: mdl-33023996
ABSTRACT
RATIONALE The European Quality of Life 5-Dimensions 5-Levels questionnaire (EQ-5D-5L) is a multidimensional patient-reported questionnaire that supports calculation of quality-adjusted life-years. Our objectives were to demonstrate feasibility of use and to calculate the minimum important difference (MID) of the EQ-5D-5L and its associated visual analogue scale (EQ-VAS) in patients with fibrotic interstitial lung disease (ILD).

METHODS:

Patients who completed the EQ-5D-5L were identified from the prospective multicentre CAnadian REgistry for Pulmonary Fibrosis. Validity, internal consistency and responsiveness of the EQ-5D-5L were assessed, followed by calculation of the MID for the EQ-5D-5L and EQ-VAS. Anchor-based methods used an unadjusted linear regression against pulmonary function tests (PFTs) and dyspnoea and other quality of life questionnaires. Distribution-based method used one-half SD and SE measurement (SEM) calculations.

RESULTS:

1816 patients were analysed, including 472 (26%) with idiopathic pulmonary fibrosis. EQ-5D-5L scores were strongly correlated with the dyspnoea and other quality of life questionnaires and weakly associated with PFTs. The estimated MID for EQ-5D-5L ranged from 0.0050 to 0.054 and from 0.078 to 0.095 for the anchor-based and distribution-based methods, respectively. The MID for EQ-VAS ranged from 0.5 to 5.0 and from 8.0 to 9.7 for the anchor-based and distribution-based methods. Findings were similar across ILD subtypes, sex and age.

CONCLUSION:

We used a large and diverse cohort of patients with a variety of fibrotic ILD subtypes to suggest validity and MID of both the EQ-5D-5L and EQ-VAS. These findings will assist in designing future clinical trials and supporting cost-effectiveness analyses of potential treatments for patients with fibrotic ILD.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicometria / Fibrose Pulmonar / Qualidade de Vida Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Psicometria / Fibrose Pulmonar / Qualidade de Vida Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2021 Tipo de documento: Article